Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IP · 1 trial · 1 indication
To evaluate the effect of food on the single-dose pharmacokinetics (PK) of NX-5948 in healthy subjects.
To evaluate the effect of food on the single-dose pharmacokinetics (PK) of NX-5948 in healthy subjects.
To evaluate the effect of fluconazole on the single dose PK of NX-5948 in healthy subjects.
To evaluate the effect of fluconazole on the single dose PK of NX-5948 in healthy subjects.
To evaluate the effect of fluconazole on the single dose PK of NX-5948 in healthy subjects.
To evaluate the effect of fluconazole on the single dose PK of NX-5948 in healthy subjects.
To evaluate the PK of NX-5948 following 2 doses of NX-5948 given 12 hours apart in healthy subjects.
To evaluate the PK of NX-5948 following 2 doses of NX-5948 given 12 hours apart in healthy subjects.
To evaluate the PK of NX-5948 following 2 doses of NX-5948 given 12 hours apart in healthy subjects.
| Arm | Type | Description |
|---|---|---|
| Part 1: Sequence 1 (Treatment A, B, C) | EXPERIMENTAL | Period 1: NX-5948 or placebo administered under fasted conditions Period 2: NX-5948 or placebo administered under fed conditions Period 3: Fluconazole and single dose of NX-5948/placebo coadministered on Day 4 |
| Part 1: Sequence 2 (Treatment B, A, C) | EXPERIMENTAL | Period 1: NX-5948 or placebo administered under fed conditions Period 2: NX-5948 or placebo administered under fasted conditions Period 3: Fluconazole and single dose of NX-5948/placebo coadministered on Day 4 |
| Part 2: NX-5948 PK | EXPERIMENTAL | Experimental: Part 2: NX-5948 PK NX-5948 or placebo administered 2 doses given 12 hours apart under fasted conditions |
| Name | Type | Description |
|---|---|---|
| IP | DRUG | NX-5948 oral |
| Matching Placebo | DRUG | Fluconazole |
Inclusion Criteria: Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the study: * Healthy, adult, male, 18-55 years of age * Subjects must follow protocol-specified contraception guidance as described in the protocol. * Continuous non-smoker who has...
IP is an investigational small molecule being developed by Nurix Therapeutics, Inc. (NASDAQ: NRIX). It is currently in Phase 1 clinical development. The drug has been studied in a completed clinical trial involving healthy volunteers, with the trial focusing on food effects, drug-drug interactions, and pharmacokinetics.
IP is being studied for use in healthy volunteers. The completed Phase 1 clinical trial (NCT06593457) was designed to evaluate the food effect, drug-drug interaction potential, and pharmacokinetics of IP in healthy adult subjects. The drug is not approved for any indication and remains in clinical development.
IP is developed by Nurix Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol NRIX. Nurix is conducting clinical research on IP as an investigational small molecule.
IP is in Phase 1 clinical development. The drug has completed one Phase 1 trial (NCT06593457) that enrolled 32 healthy male participants in the United States. IP is investigational and has not been approved by regulatory authorities.
IP has been studied in one completed Phase 1 clinical trial, NCT06593457, titled 'A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects.' The trial enrolled 32 healthy male volunteers aged 18 years and older in the United States.
Yes, IP is also known as NX-5948. The clinical trial record for IP, NCT06593457, refers to the drug as NX-5948 in its title. Both names refer to the same investigational small molecule being developed by Nurix Therapeutics.